Takeda Launches CDPATH(TM), a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease PressReach · Sep 14, 2022
BD Launches Next Generation Prefillable Vaccine Syringe Designed for Reliability, Efficiency PressReach · Sep 13, 2022
Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates PressReach · Sep 13, 2022
Illumina Genomics Forum to Convene Leading Visionaries to Explore Architecting Health's Radically New Infrastructure PressReach · Sep 13, 2022
More than 2,000 Biopharma Leaders Come Together at Veeva R&D and Quality Summit to Advance Drug Development PressReach · Sep 13, 2022
Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMML PressReach · Sep 12, 2022
Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214 PressReach · Sep 12, 2022
Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors PressReach · Sep 12, 2022
Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022 PressReach · Sep 10, 2022